갑상선의 휘틀세포암 12예
Hurthle Cell Carcinoma of the Thyroid: A Case Report of 12 Cases
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Hurthle cell carcinoma (HCC) is a relatively rare disease, which comprises about 3% of differentiatedthyroid carcinoma. HCC is considered to have more aggressive clinical behavior comparedwith other differentiated thyroid carcinoma. However, there has been no consensus aboutclinical behavior and optimal treatment of HCC because of insufficient reports. Moreover,owing to geographical characteristics, HCC is rarer in Korea than in western countries. Basedon 2017 World Health Organization classification, HCC is newly classified as an individualgroup, not as a subtype of follicular thyroid carcinoma. Therefore, we report data of 12 HCCpatients who underwent surgery in our center from January 2000 to May 2020 with a reviewof the literature.
Abstract
Hurthle cell carcinoma (HCC) is a relatively rare disease, which comprises about 3% of differentiatedthyroid carcinoma. HCC is considered to have more aggressive clinical behavior comparedwith other differentiated thyroid carcinoma. However, there has been no consensus aboutclinical behavior and optimal treatment of HCC because of insufficient reports. Moreover,owing to geographical characteristics, HCC is rarer in Korea than in western countries. Basedon 2017 World Health Organization classification, HCC is newly classified as an individualgroup, not as a subtype of follicular thyroid carcinoma. Therefore, we report data of 12 HCCpatients who underwent surgery in our center from January 2000 to May 2020 with a reviewof the literature.
참고문헌 (13)
- Goffredo P, "Hurthle cell carcinoma: A population-level analysis of 3311 patients", Cancer, 119(3), pp.504~511 (2013)
- Moon SS, "Hurthle cell tumor of the thyroid gland", Korean J Head Neck Oncol, 8(2), pp.106~116 (1992)
- 이잔디, "갑상선 휘틀세포암(Hurthle Cell Carcinoma)의 임상적 특징 및 예후인자: 순수 소포상 갑상선암과의 비교", Annals of Surgical Treatment and Research, 74(2), pp.91~97 (2008), 대한외과학회
- Cibas ES, "The bethesda system for reporting thyroid cytopathology", Am J Clin Pathol, 132(5), pp.658~665 (2009)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
- Kim TH, "Tumor size and age predict the risk of malignancy in Hürthle cell neoplasm of the thyroid and can therefore guide the extent of initial thyroid surgery", Thyroid, 20(11), pp.1229~1234 (2010)
- Kakudo K, "The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives", Pathol Int, 68(12), pp.641~664 (2018)
- "Clinical practice guidelines in oncology-thyroid carcinoma. version 1" (2020)[URL]
- Stojadinovic A, "Hürthle cell carcinoma : A 60-year experience", Ann Surg Oncol, 9(2), pp.197~203 (2002)
- Ahmadi S, "Hürthle cell carcinoma:Current perspectives", Onco Targets Ther, 9, pp.6873~6884 (2016)
- Pryma DA, "Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients", J Nucl Med, 47(8), pp.1260~1266 (2006)
- McHenry CR, "Follicular adenoma and carcinoma of the thyroid gland", Oncologist, 16(5), pp.585~593 (2011)
- Bhattacharyya N, "Survival and prognosis in Hürthle cell carcinoma of the thyroid gland", Arch Otolaryngol Head Neck Surg, 129(2), pp.207~210 (2003)